Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Precigen (NASDAQ:PGEN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.
Analyst Ratings
This is a summary of recent ratings for Fate Therapeutics and Precigen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Precigen | 1 | 1 | 4 | 0 | 2.50 |
Fate Therapeutics presently has a consensus price target of $5.80, suggesting a potential upside of 531.12%. Precigen has a consensus price target of $13.25, suggesting a potential upside of 214.73%. Given Fate Therapeutics’ higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Precigen.
Profitability
This table compares Fate Therapeutics and Precigen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,941.09% | -73.92% | -45.16% |
| Precigen | 15.55% | 57.93% | 14.43% |
Valuation & Earnings
This table compares Fate Therapeutics and Precigen”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $6.65 million | 16.80 | -$136.32 million | ($1.03) | -0.89 |
| Precigen | $9.68 million | 155.94 | -$250.64 million | $0.10 | 42.10 |
Fate Therapeutics has higher earnings, but lower revenue than Precigen. Fate Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Fate Therapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.
Summary
Precigen beats Fate Therapeutics on 8 of the 12 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biotechnology company based in San Diego, California. It develops cellular immunotherapies using induced pluripotent stem cells (iPSCs), which can be engineered and used to produce populations of therapeutic cells. The company’s research focuses on off-the-shelf cell therapies, including natural killer (NK) cell and T-cell programs designed to target cancer. Its approach aims to create standardized therapies that do not require cells to be collected from each individual patient.
About Precigen
Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies, including engineered immunotherapies. The company is based in Germantown, Maryland, and its roots include Intrexon, which adopted the Precigen name in 2020. Its approved product, PAPZIMEOS (zopapogene imadenovec-drba), is a gene therapy for adults with recurrent respiratory papillomatosis, a rare condition associated with human papillomavirus types 6 and 11. Precigen is also developing investigational therapies for cancers and other diseases.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
